Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Solid Biosciences Inc | SLDB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
14.25 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 1.81 - 14.99 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 14.25 | USD |
Solid Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
538.04M | 37.76M | - | 8.09M | -85.98M | -2.28 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Solid Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SLDB Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 13.38 | 14.99 | 11.6511 | 13.51 | 314,124 | 0.87 | 6.50% |
1 Month | 9.68 | 14.99 | 8.60 | 12.55 | 334,976 | 4.57 | 47.21% |
3 Months | 5.29 | 14.99 | 5.20 | 9.03 | 369,048 | 8.96 | 169.38% |
6 Months | 2.51 | 14.99 | 1.81 | 6.05 | 430,277 | 11.74 | 467.73% |
1 Year | 3.92 | 14.99 | 1.81 | 6.00 | 224,276 | 10.33 | 263.52% |
3 Years | 87.75 | 88.05 | 1.81 | 27.82 | 566,488 | -73.50 | -83.76% |
5 Years | 143.25 | 203.70 | 1.81 | 55.88 | 848,562 | -129.00 | -90.05% |
Solid Biosciences Description
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of speciality and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. Its lead product candidate, the SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices. |